 |
21 Diseases |  |
26 Trials |
|
26 Trials |  |
3632 News |  |
| «12345678910111213...3536» |
- || Retrospective data, Review, Journal: Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis. (Pubmed Central) - Nov 8, 2023
Secukinumab, ixekizumab and infliximab are effective for PP. Research is warranted to produce evidence about the efficacy of biologics in PP and PPP.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
PHOTOSENSITIVE PSORIASIS SUCCESSFULLY TREATED WITH IXEKIZUMAB: A CASE REPORT () - Nov 6, 2023 - Abstract #ISDS2023ISDS_276;
There are no established directives for the treatment of photosensitive psoriasis. Our case report presents evidence supporting ixekizumab in the treatment of photosensitive psoriasis.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Cosentyx (secukinumab) / Novartis
The long-term effectiveness of biologics in Chinese patients with psoriasis by body regions: A retrospective real-life study () - Nov 6, 2023 - Abstract #ISDS2023ISDS_236;
In this study, we finally enrolled 464 patients, including 79 adalimumab and its biosimilars, 278 secukinumab, 55 ixekizumab, and 52 ustekinumab. Overall, this study provided the real-world experience in clinical remission rate of biologics by body regions among Chinese population and demonstrated that psoriasis lesions on the head and neck and the lower extremities are the most difficult to treat.
- Comparison of the disease survival of biologics for the treatment of moderate-to-severe psoriasis: real-world data () - Nov 6, 2023 - Abstract #ISDS2023ISDS_230;
Objective: This study aims to assess the drug survival, efficacy and safety between anti-IL23 and anti-IL17 groups of biologics and among each individual biologics (Guselkumab, Secukinumab, Ixekizumab, Risankizumab). In this double-center, retrospective cohort study, the four biologics
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Transcriptomic Analysis of Plaque Psoriasis during Anti-IL-17A Biologic Therapy and Drug Withdrawal () - Nov 6, 2023 - Abstract #ISDS2023ISDS_222;
Our findings indicate that there is an inflammatory rebound at the transcriptomic level during the early stage of relapse, highlighting the potential of mast cell-targeted treatment to sustain disease remission. Inhibiting chemokine receptors like CCR6 has the potential to prevent relapse, mitigate psoriatic metabolic co-morbidities.
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Trial primary completion date: Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris (clinicaltrials.gov) - Nov 2, 2023
P1, N=10, Recruiting, Sponsor: University of New Mexico
Inhibiting chemokine receptors like CCR6 has the potential to prevent relapse, mitigate psoriatic metabolic co-morbidities. Trial primary completion date: Aug 2023 --> Aug 2024
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Observational data, Journal: Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study. (Pubmed Central) - Oct 30, 2023
Trial primary completion date: Aug 2023 --> Aug 2024 Ixekizumab was well tolerated and effective in real-world clinical practice in Chinese adults with moderate-to-severe plaque psoriasis.
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Cosentyx (secukinumab) / Novartis
Retrospective data, Journal, Real-world evidence, Real-world: Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study. (Pubmed Central) - Oct 30, 2023
Most of the patients with PsA treated with anti-IL17 in Spain had moderate to severe disease activity, high peripheral joint and skin involvement, and had received previous b/tsDMARDs. More than 80% of patients with a 1-year follow-up persisted on anti-IL17, with the highest rate observed in the IXE cohort, followed by the SECU150 then SECU300 cohorts.
- || Review, Journal: IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa. (Pubmed Central) - Oct 28, 2023
monoclonal antibody, is the only approved biologic agent for HS, obtaining a therapeutic response in only 50% of HS patients...Both bimekizumab and secukinumab, targeting IL-17 in different manners, have successfully completed phase III trials with promising results; the latter has recently been approved by EMA for the treatment of HS. The aim of this review is to summarize the current state of knowledge concerning the relevant role of IL-17 in HS pathogenesis, highlighting the key clinical evidence of anti-IL-17 agents in the treatment of this disease.
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Journal: Tofacitinib combined with local low-dose ixekizumab injection benefits those with peripheral psoriatic arthritis. (Pubmed Central) - Oct 27, 2023
The aim of this review is to summarize the current state of knowledge concerning the relevant role of IL-17 in HS pathogenesis, highlighting the key clinical evidence of anti-IL-17 agents in the treatment of this disease. No abstract available
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Tremfya (guselkumab) / J&J
Journal, HEOR, Patient reported outcomes: Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO). (Pubmed Central) - Oct 26, 2023
This subgroup analysis showed that anti-IL-17A biologics are effective at rapidly improving signs and symptoms of PsO and improving quality of life. Additionally, serial photography provided visual evidence of biologic treatment response over time.
- | Retrospective data, Journal, Head-to-Head: Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis. (Pubmed Central) - Oct 23, 2023
The interleukin-17A inhibitor ixekizumab has the highest rate of complete nail clearance and it can be considered the best-ranked therapy from the present evidence. This study is relevant to daily practice as it facilitates the decision when choosing between the wide variety of available biologics in patients for whom clearance of nail symptoms is the first concern.
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Journal, HEOR, Real-world evidence, Real-world: Quality of life benefit and clinical predictors of complete skin clearance in psoriasis: a multicenter, prospective, real-world study. (Pubmed Central) - Oct 22, 2023
This study highlights the fact that clinical parameters are important in determining CSC response in psoriasis. In daily practice, achieving CSC represents a clinically meaningful treatment goal, especially from the patient perspective.
- | Journal: Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks. (Pubmed Central) - Oct 6, 2023
Among biologics included in these two NMAs, ixekizumab has the highest absolute probability of achieving complete resolution of NP. Results may help to inform treatment decisions for patients with NP.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Ixekizumab Trough Concentrations in Psoriasis: Paving the Way towards Personalized Therapy - A Cohort Study (e-Poster Hall) - Sep 27, 2023 - Abstract #EADV2023EADV_4632;
Results may help to inform treatment decisions for patients with NP. These results suggest an exposure-response relationship for IXE in standard maintenance dose in real-world, adult psoriasis patients, and propose an optimal effective steady-state TC of 3.4
- Humira (adalimumab) / AbbVie
Drug survival of interleukin-23 p19 inhibitors compared to other biologics for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) (Hall B) - Sep 27, 2023 - Abstract #EADV2023EADV_4582;
The results of this study, which includes the largest cohort of psoriasis patients on IL-23p19 inhibitors reported thus far, showed guselkumab and risankizumab had similar drug survival and had the highest drug survival associated with both effectiveness and safety compared with other biologics in BADBIR. Our findings should be taken into consideration for people with psoriasis who value treatment effect longevity and are due to commence biologic therapy.**
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Cosentyx (secukinumab) / Novartis
The Effects of Interleukin 17 Inhibitors on Major Adverse Cardiovascular Events in Patients Na (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4227;
Flow chart of included randomized controlled trials. Relative Risks (RRs) of all major adverse cardiovascular events (MACEs) in patients with psoriasis (PsO) and/or psoriatic arthritis (PsA) treated with interleukin 17 (IL-17) inhibitors compared with placebo or disease-modifying antirheumatic drugs (DMARDs) in randomized controlled trials (RCTs) using the Mantel-Haenszel (M-H) random-effect method.
- Humira (adalimumab) / AbbVie
Real-World Switching and Discontinuation Patterns for Biologic Disease-Modifying Antirheumatic Drugs in Patients with Active Psoriatic Arthritis in Japan (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4219;
While treatment switch rates varied across bDMARDs, discontinuation rates were lowest for RZB at each timepoint that was examined. Hazards of switching or discontinuation relative to RZB were generally higher across most bDMARDs, indicating higher treatment persistence rates for RZB.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Irrespective of the Number of Erosions at Baseline, Patients with Psoriatic Arthritis Treated with Ixekizumab Show Improved Clinical Outcomes (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4215;
P3
Higher response rates (e.g., ACR50/70) were also harder to achieve in pts with higher BES. Irrespective of BES, IXE treated pts showed greater improvement compared to PBO in the achievement of LDA and functional outcomes.
- Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNF? Inhibitors (IL-17Ai or TNFi) (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4213;
Persistence to therapy can be especially important in chronic, progressive diseases like PsA where patients will likely have to change treatment regimens over the course of disease. Results from this study indicate that IL-17Ai biologics can represent a viable, long-lived treatment choice even among patients with prior biologic experience and high comorbidity burden.
- Rinvoq (upadacitinib) / AbbVie
Upadacitinib in Refractory Psoriatic Arthritis. Multicenter Study of 134 Patients in Clinical Practice (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4210;
In addition, they received the following ts-DMARDs: Tofacitinib (n=29), Apremilast (27), Filgotinib (1). UPA at baseline was associated with: a) prednisone (43.3%; mean dose 8.3
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Ixekizumab Significantly Improves Nail Disease and Adjacent Joint Tenderness and Swelling in Psoriatic Arthritis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4205;
P4
At the group level, SPIRIT-H2H patients treated with ixekizumab (IXE) achieved significantly greater improvements in nail PsO compared to those treated with adalimumab (ADA) 5 . IXE treatment showed a significant advantage over ADA in resolving nail PsO, joint tenderness, and joint swelling among the finger units with nail and adjacent joint disease of patients with PsA.
- Exploring Metabolite Markers Associated with Treatment Response of Biologic Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis Patients (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4190;
Patients were treated with either TNFi (n = 20; infliximab, adalimumab, etanercept, certolizumab or golimumab) or IL-17Ai (n = 20; secukinumab or ixekizumab). The identification of cotinine
- The Association of Body Mass Index with SARS-CoV-2 Infection (COVID-19) in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3801;
This could be due to upregulation of angiotensin-converting enzyme 2 (ACE2) receptors found in adipose tissues and impaired viral elimination as a result of disease-related and/ or obesity-induced blunted immune response and chronic inflammation [1]. Severe SARS-CoV-2 infections in this cohort were rare.Optimization of BMI may contribute to reducing risk and severity of COVID-19 infection.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
How Do Early Disease Activity and Early Clinical Response Associate with Long-Term Outcomes with Ixekizumab in Radiographic Axial Spondyloarthritis? (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2647;
P3
Severe SARS-CoV-2 infections in this cohort were rare.Optimization of BMI may contribute to reducing risk and severity of COVID-19 infection. These data regarding IXE-treated patients with r-axSpA reinforce the current ASAS-EULAR and T2T recommendations, in that those who achieved ASDAS CII or ASDAS < 2.1 at W12 and/or W24 were highly likely to attain the treatment target of ID or LDA at W52.
- Comparisons of the Risk of Serious Infections Associated with the Different Classes of Targeted Therapies Used in Psoriatic Arthritis Patients: A Nationwide Cohort Study from the French Health Insurance Database (Room 33A-C; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2074;
Compared with new users of adalimumab, this risk was lower among new users of etanercept and ustekinumab, with no difference among new users of the other TNF i , IL17 i or JAK i . Given the numerous therapeutic options available for PsA treatment, these findings could assist physicians in optimizing their therapeutic strategies based on individual patients' characteristics.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Effect of Ixekizumab Treatment on MRI Structural Lesions in the Sacroiliac Joints of Patients with Radiographic Axial Spondyloarthritis; A Post-hoc Analysis of a Placebo and Active Controlled RCT (Exhibit Hall A-B; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2061;
P3
Given the numerous therapeutic options available for PsA treatment, these findings could assist physicians in optimizing their therapeutic strategies based on individual patients' characteristics. This analysis evaluated the effect of IXE versus placebo and active control, adalimumab (ADA), on structural lesions in SIJ assessed by MRI at week 16 in bio-na
- ||| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Clinical, P3 data, Journal: Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study. (Pubmed Central) - Sep 22, 2023
P3
This analysis evaluated the effect of IXE versus placebo and active control, adalimumab (ADA), on structural lesions in SIJ assessed by MRI at week 16 in bio-na IXEQ4W was associated with rapid and significant improvements in the signs and symptoms of active r-axSpA in Chinese patients at week 16 that were sustained at week 52, with no new safety signals.
- Novel Psoriasis Agents Associated Cardiotoxicity: Analysis of FAERS (Zone 3, Science and Technology Hall, Level 2) - Sep 21, 2023 - Abstract #AHA2023AHA_6824;
The study uncovers unknown cardiovascular adverse effects related to biologic agents used in psoriasis treatment. These findings emphasise the importance of monitoring and evaluating the cardiovascular safety profiles of biologic agents used in psoriasis treatment.
- | Journal: Does biological agent treatment have an impact on serum uric acid levels in patients with psoriasis? (Pubmed Central) - Sep 19, 2023
Statistically significant decrease in serum uric acid levels was detected in patients treated with adalimumab (p?<?0.001), infliximab (p?=?0.002), ixekizumab (p?=?0.001), secukinumab (p?=?0.012) and ustekinumab (p?<?0.001). Since high serum uric acid levels have been associated with increased risk for cardiovascular diseases and metabolic syndrome, treatment of psoriasis with adalimumab, infliximab, ixekizumab, secukinumab and ustekinumab may have a positive impact on cardiometabolic comorbidities.
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Humira (adalimumab) / AbbVie
Journal: Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa. (Pubmed Central) - Sep 18, 2023
Since high serum uric acid levels have been associated with increased risk for cardiovascular diseases and metabolic syndrome, treatment of psoriasis with adalimumab, infliximab, ixekizumab, secukinumab and ustekinumab may have a positive impact on cardiometabolic comorbidities. No abstract available
- || Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Clinical, Journal: Anti-Interleukin-17s for successful management of pustular psoriasis. (Pubmed Central) - Sep 8, 2023
We also provide a brief overview of the current knowledge concerning the role of IL-17 in PP pathogenesis and of the use of IL-17 inhibitors in the treatment of PP. Based on our experience, anti-IL-17 molecules may represent a valuable therapeutical option for patients affected by different PP subtypes.
- Therapeutics in immune-mediated diseases and fertility: what is the evidence of safety? (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_4415;
Based on our experience, anti-IL-17 molecules may represent a valuable therapeutical option for patients affected by different PP subtypes. The evidence are mostly dependent on low level evidence and will be demonstrated but it is certain that more studies and even case series need to be conducted in this area.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese Psoriasis Real World Evidence Research Group (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_4181;
The evidence are mostly dependent on low level evidence and will be demonstrated but it is certain that more studies and even case series need to be conducted in this area. Our real-world data demonstrated the safety and effectiveness of adalimumab, secukinumab, and ixekizumab in children with psoriasis.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Alterations in metabolite, lipid, and cytokine concentrations in plasma samples of psoriatic patients treated with either ixekizumab or risankizumab (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_3947;
Quantification of metabolites, lipids and cytokines from plasma display a feasible method to perform monitoring and prediction. In addition, obtained data from this study help to better understand downstream effects of initially elevated cytokines IL-17 and IL-23 in psoriatic patients.
- Consider skin biopsy in patient with unexpected poor response to biological therapy for psoriasis (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2797;
inhibitors, there are increasing reports for more temporary agents, such as ustekinumab, secukinumab and ixekizumab. As we expect resolution of this case, we can only emphasize the importance of performing biopsy in cases of atypical
- Risk of Onset of Serious Infections in Psoriatic Patients Treated with either TNF-a, IL-17, or IL-23 Inhibitors: Results from a Retrospective Global Cohort (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2793;
Based on our results it might be necessary to include patient monitoring for infectious diseases under long-term therapy with biologics. However, further real-world data on the long-term safety of biologics are required.
- The risk of onset of malignancies and major cardiovascular diseases in psoriatic patients treated with either TNF-?, IL-23, or IL-17 inhibitors: results from a global retrospective study cohort. (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2791;
Our findings indicate that subsequent screenings for reported malignancies and MACEs should be included into daily clinical practice especially following treatment initiation with TNF-? inhibitors, as compared to treatment with IL-23 or IL-17 inhibitors.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Long-term clinical efficacy and safety of ixekizumab for psoriatic patients: a single-center experience (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2776;
However, there is limited evidence over the real-world survival of apremilast in patients with psoriasis in the long term. This study confirms the efficacy and safety of ixekizumab in real-world clinical practice.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Injection Experience Satisfaction with a New, Citrate-Free Formulation of Ixekizumab in the United States Customer Support Program (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2775;
Most patients who switched from original ixekizumab were satisfied with their first injection experience, were willing to continue using and recommend to others, and preferred the new formulation. Similar findings were seen for those newly initiating citrate-free ixekizumab.
- Onset of vitiligo in psoriasis patients on interleukin-17 inhibitors (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2774;
The physicians should be aware of the possibility of new-onset vitiligo during biological therapy. Successful biological treatment strategy should not be discontinued unless the impact of vitiligo on quality of life outweighs the benefits of biological therapy for the underlying inflammatory disease.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Eruptive lentiginosis confined to areas of resolving psoriatic plaques in a patient with erythrodermic psoriasis treated with ixekizumab (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2743;
Successful biological treatment strategy should not be discontinued unless the impact of vitiligo on quality of life outweighs the benefits of biological therapy for the underlying inflammatory disease. With only a few known cases, ELRP has been reported to arise from systemic biologics and non-biologics (methotrexate and apremilast)...This is the case of a 16-year-old Filipino male with erythrodermic psoriasis who received a combined systemic treatment of methotrexate and cyclosporine along with topical steroids for 6 months with minimal response...To the author
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Ixekizumab induces early clinical resolution of pityriasis rosea: a prospective real-world study (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2730;
With only a few known cases, ELRP has been reported to arise from systemic biologics and non-biologics (methotrexate and apremilast)...This is the case of a 16-year-old Filipino male with erythrodermic psoriasis who received a combined systemic treatment of methotrexate and cyclosporine along with topical steroids for 6 months with minimal response...To the author In conclusion, IL17A inhibitors are effective and safe in the treatment of patients with pityriasis rosea.
- Real world survivability of IL-17 inhibitors for psoriasis patients; results from a UK Dermatology Department (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2724;
Limitations identified include relatively low patient numbers, which do not allow detailed statistical analysis. Further real world data focussing on long term follow up for patients on all types of IL-17 inhibitors are necessary to accurately gauge treatment.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Extended dosing intervals of ixekizumab for psoriasis: a prospective real-world study (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2717;
Further real world data focussing on long term follow up for patients on all types of IL-17 inhibitors are necessary to accurately gauge treatment. Extended-interval dosing of ixekizumab in China is an effective, safety and economic way in the treatment of psoriasis.
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Long term psoriasis control with guselkumab versus secukinumab and ixekizumab among bio-experienced patients: analysis of drug persistence in large claims database (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2703;
Extended-interval dosing of ixekizumab in China is an effective, safety and economic way in the treatment of psoriasis. Among bio-experienced patients with psoriasis, initiation of guselkumab was associated with the greater persistence compared to secukinumab or ixekizumab in a real-world setting, potentially indicative of better long-term psoriasis control.
- Bimzelx (bimekizumab) / UCB
Hidradenitis suppurativa, axial spondylarthritis, and pyoderma gangrenosum successfully treated with bimekizumab (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2279;
Its novel mechanism of action resulted in rapid and clinically meaningful improvements that translated into better outcomes for the patient. In our experience, bimekizumab was also effective for the treatment of pyoderma gangrenosum.
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / AbbVie
Journal: Prescription Trends of Biologic DMARDs in Treating Rheumatologic Diseases: Changes of Medication Availability in COVID-19. (Pubmed Central) - Aug 25, 2023
Overall, the prescription trends of biologic DMARDs for rheumatologic diseases did not vary significantly in the University Hospital of Split, Croatia. Tocilizumab was prescribed less during COVID-19 due to shortages, while ixekizumab was more prescribed during COVID-19 due to an increase in psoriatic arthritis patients processed and due to being approved for treating AS.
- || Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Review, Journal: Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium. (Pubmed Central) - Aug 23, 2023
A literature search was performed for articles published through December 2022. Ixekizumab is one of the most efficacious biologics for psoriasis, with a rapid onset of response, favorable long-term outcomes and an adequate safety profile.
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Retrospective data, Journal: Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study). (Pubmed Central) - Aug 21, 2023
The quality of life of patients also improved significantly starting at Week 12, with sustained effect in the long term. This 24-month observational cohort study confirmed that ixekizumab is effective in the long-term management of patients with moderate-to-severe plaque psoriasis.